Loading clinical trials...
Loading clinical trials...
A Randomized Double-Blind, Placebo Controlled Trial of Abatacept (CTLA4-Ig) in Giant Cell Arteritis (ABAGART)
Conditions
Interventions
Abatacept
Placebo
Locations
9
United States
Mayo Clinic
Rochester, Minnesota, United States
Hospital for Special Surgery
New York, New York, United States
Cleveland Clinic
Cleveland, Ohio, United States
University of Pennsylvania
Philadelphia, Pennsylvania, United States
Vanderbilt University
Nashville, Tennessee, United States
University of British Columbia
Vancouver, British Columbia, Canada
Start Date
March 29, 2021
Primary Completion Date
December 1, 2029
Completion Date
December 1, 2029
Last Updated
January 23, 2026
NCT07246577
NCT04402086
NCT06887062
NCT05865054
NCT07001059
NCT06609668
Lead Sponsor
University of Pennsylvania
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions